Changing How We Treat Systemic Sclerosis
In this three-part series dedicated to the physician's perspective on living with a rare disease, Conference Forum reporter Danny McCarthy sits down with Tracy Frech, MD, to discuss Systemic Sclerosis...
19 Mar 202024min
New Opportunities for Cell Therapy Combinations
In this podcast moderated by Dr Michael Kalos, Janssen Oncology, you will hear a panel discussion from the 2019 IO Combinations 360° conference. Topic points include: What are the new opportunities in...
10 Mar 202046min
PD1 Resistance with a Multi-Omic Approach
Anti-PD-1 therapy has transformed cancer care but most patients do not respond. It is increasingly clear that there will be no single biomarker of response to a PD-1, and that a multi-omic approach wi...
10 Mar 202025min
Updates on PARP Inhibition
In this podcast, first recorded at the 4th annual IO Combinations 360° conference, Dr Darren Hodgson, AstraZeneca presented updates on PARP inhibition. Topics include: Strategies to target homologous ...
9 Mar 202025min
Leveraging the Tumor Microenvironment for IO Therapy
First recorded at the 4th annual IO Combinations 360° conference, this talk provided by Dr Kenneth Hance, GSK addresses agonistic strategies, T and NK cell redirection and the use of genetic/phenotypi...
8 Mar 202019min
Updates on Bintrafusp alfa/M7824 Clinical Data
In this podcast, first recorded at the 4th annual IO Combinations 360° conference, Dr Laureen Ojalvo, EMD Serono provides an overview of the moleculte Bintrafusp alfa/M7824. This molecule is an innova...
7 Mar 202024min
NKTR-214: Harnessing the IL-2 Pathway in Combination Immunotherapies
In this podcast, first recorded at the 4th annual IO Combinations 360° conference, Dr Willem Overwijk, Nektar Therapeutics discusses Bempegaldesleukin (NKTR-214): harnessing the IL-2 pathway in combin...
6 Mar 202020min
Advancing Bispecifics for Combination Immunotherapy
First recorded at the fourth annual IO Combinations 360° conference, this panel moderated by Dr Daniel Chen, IGM Biosciences discusses advancing bispecifics for combination immunotherapy. This discuss...
2 Mar 202043min
